ESMO 2022 | The emerging continuum of care in metastatic kidney cancer in the second-line and beyond

Camillo Guglielmo Porta, MD, University of Bari Aldo Moro, Bari, Italy, discusses the emerging continuum of care in metastatic kidney cancer in the second-line and beyond. Currently, the standard of care for first-line treatment of metastatic kidney cancer is represented by a combination of an antiangiogenic with an immune checkpoint inhibitor. Available data suggests a VEGFR tyrosine kinase inhibitor (TKI) may be used following progression on SOC first-line treatment, so long as it has not used in the first-line combination. Data is also indicating rechallenging with immunotherapy may be sufficient, however, the development of novel agents may provide a more promising approach to improving patient outcomes in this setting. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.